Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Rheumatoid Arthritis Q&As

Lars Klareskog, MD
Q&A
Lars Klareskog, MD, on the Study of Occupational Exposures and Risk of RA
08/08/2023
Dr Klareskog agreed to answer a few questions about this study on whether occupational inhalable agents present major risks in the development of rheumatoid arthritis, particularly among smokers and among those with a genetic predisposition...
Dr Klareskog agreed to answer a few questions about this study on whether occupational inhalable agents present major risks in the development of rheumatoid arthritis, particularly among smokers and among those with a genetic predisposition...
Dr Klareskog agreed to answer a...
08/08/2023
Rheumatology & Arthritis
Q&As
4 Questions About Inhibitor of DNA Binding 1 Protein in Rheumatoid Arthritis
11/27/2019
Inhibitor of DNA binding 1 (ID-1) is a nuclear transcription factor that controls transcriptional activation of target genes. Previous research indicates that ID-1 may contribute to angiogenesis and vasculogenesis...
Inhibitor of DNA binding 1 (ID-1) is a nuclear transcription factor that controls transcriptional activation of target genes. Previous research indicates that ID-1 may contribute to angiogenesis and vasculogenesis...
...
11/27/2019
Rheumatology & Arthritis
Q&As
4 Questions About Methotrexate-Based Treatment Strategies in Early RA
10/02/2019
Methotrexate (MTX) has remained an integral part of the management of rheumatoid arthritis (RA) and other rheumatic conditions over time, despite numerous therapeutic advances. Still, studies that describe real-world...
Methotrexate (MTX) has remained an integral part of the management of rheumatoid arthritis (RA) and other rheumatic conditions over time, despite numerous therapeutic advances. Still, studies that describe real-world...
...
10/02/2019
Rheumatology & Arthritis

Advertisement

Q&As
5 Questions About Anti-MAA Antibodies in RA-Associated Interstitial Lung Disease
09/06/2019
Individuals with rheumatoid arthritis (RA) have an increased risk of premature mortality. Those with RA-associated interstitial lung disease (RA-ILD) have an even greater risk, with a median survival of 3 years after...
Individuals with rheumatoid arthritis (RA) have an increased risk of premature mortality. Those with RA-associated interstitial lung disease (RA-ILD) have an even greater risk, with a median survival of 3 years after...
...
09/06/2019
Rheumatology & Arthritis
Q&As
4 Questions About RAPID3 for RA
09/03/2019
Previous studies have suggested routine assessment of patient index data 3 (RAPID3) is reliable and convenient for monitoring disease activity in rheumatoid arthritis (RA). A prospective study led by Michael Ward, MD,...
Previous studies have suggested routine assessment of patient index data 3 (RAPID3) is reliable and convenient for monitoring disease activity in rheumatoid arthritis (RA). A prospective study led by Michael Ward, MD,...
Previous...
09/03/2019
Rheumatology & Arthritis
Q&As
5 Questions About Asthma and Rheumatoid Arthritis
06/27/2019
It has been thought that rheumatoid arthritis (RA) originates at mucosal surfaces, particularly in the airway mucosa. To determine whether this hypothesis is correct, researchers led by Vanessa Kronzer, MD, who is...
It has been thought that rheumatoid arthritis (RA) originates at mucosal surfaces, particularly in the airway mucosa. To determine whether this hypothesis is correct, researchers led by Vanessa Kronzer, MD, who is...
It has...
06/27/2019
Rheumatology & Arthritis

Advertisement

Q&As
5 Questions About DMARDs in RA
04/18/2019
Methotrexate is recommended as initial treatment for patients with rheumatoid arthritis (RA). However, treatment strategies can be altered if methotrexate does not meet treatment targets. Available data on the...
Methotrexate is recommended as initial treatment for patients with rheumatoid arthritis (RA). However, treatment strategies can be altered if methotrexate does not meet treatment targets. Available data on the...
...
04/18/2019
Rheumatology & Arthritis

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Stay in the Know

Rheumatology & Arthritis Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Partner Spotlight

Axial Involvement in SpA: A Patient-Centered Exploration, Chapter 1
SPONSORED
Axial Involvement in SpA, Chapter 1
04/26/2022
Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.
Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.
Ethan Craig, MD, MPH, discusses...
04/26/2022
Rheumatology & Arthritis

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Popular Articles

office+man working
News
Ranking Patient-Reported Outcome Measures for Patients With PsA
06/21/2023

Priyam Vora, Digital Associate Editor

Priyam Vora, Digital Associate Editor...
Investigators sought to establish the responsiveness to therapy and minimum clinically important improvement for patient-reported outcome measures in psoriatic arthritis.
Investigators sought to establish the responsiveness to therapy and minimum clinically important improvement for patient-reported outcome measures in psoriatic arthritis.
Investigators sought to...
06/21/2023
Rheumatology & Arthritis
Matthew Baker
Podcast
Matthew Baker, MD, on Interstitial Lung Disease Among Patients With RA Treated with DMARDs
08/22/2023
Dr Baker reviews the findings of his recent research into the association of interstitial lung disease among patients with rheumatoid arthritis who have been treated with both biologic and targeted disease-modifying antirheumatic drugs.
Dr Baker reviews the findings of his recent research into the association of interstitial lung disease among patients with rheumatoid arthritis who have been treated with both biologic and targeted disease-modifying antirheumatic drugs.
Dr Baker reviews the findings of...
08/22/2023
Rheumatology & Arthritis
Philip Mease
Podcast
Philip Mease, MD, on Assessing Treatment Response in PsA by Disease Domain
10/29/2023
In this podcast, Dr Philip Mease reviews recent research on the importance of assessing treatment response across all domains of psoriatic arthritis, including skin, joints, entheses, and more.
In this podcast, Dr Philip Mease reviews recent research on the importance of assessing treatment response across all domains of psoriatic arthritis, including skin, joints, entheses, and more.
In this podcast, Dr Philip Mease...
10/29/2023
Rheumatology & Arthritis
Conference Coverage
Black Box Warning No Deterrent to JAKi Adherence in RA
12/27/2023

Rebecca Mashaw, Digital Managing Editor

Rebecca Mashaw, Digital Managing Edit...
A retrospective cohort study found that patients with rheumatoid arthritis treated with Janus kinase inhibitors were no less adherent to their medication regimen after the addition of a black box warning by the US Food and Drug Administration
A retrospective cohort study found that patients with rheumatoid arthritis treated with Janus kinase inhibitors were no less adherent to their medication regimen after the addition of a black box warning by the US Food and Drug Administration
A retrospective cohort study...
12/27/2023
Rheumatology & Arthritis
News
Ultrasound in the Management of PsA
01/29/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
The findings suggest the interest of rheumatologists to use ultrasound in the management of psoriatic arthritis.
The findings suggest the interest of rheumatologists to use ultrasound in the management of psoriatic arthritis.
The findings suggest the...
01/29/2024
Rheumatology & Arthritis

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use